web231003

LONSURF® + bevacizumab for the Treatment of 3L Metastatic Colorectal Cancer

Date

October 3, 2023

Explore related products in the following collection:

JADPRO Webinar Series

Speaker

Kirollos Hanna, PharmD

Minnesota Oncology

Related Products

Thumbnail for Intervene With Jakafi® (ruxolitinib) at the First Sign of Initial Systemic Treatment Failure in Chronic GVHD: A Real-World, Case-Based Discussion

Intervene With Jakafi® (ruxolitinib) at the First Sign of Initial Systemic Treatment Failure in Chronic GVHD: A Real-World, Case-Based Discussion

Thumbnail for Discussion of BRUKINSA for adult patients with CLL/SLL

Discussion of BRUKINSA for adult patients with CLL/SLL

Thumbnail for Discussion of BRUKINSA for adult patients with CLL/SLL

Discussion of BRUKINSA for adult patients with CLL/SLL

Thumbnail for LONSURF® + bevacizumab for the Treatment of 3L Metastatic Colorectal Cancer

LONSURF® + bevacizumab for the Treatment of 3L Metastatic Colorectal Cancer